# Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

> **NCT06482905** · PHASE1 · RECRUITING · sponsor: **Tcelltech Inc.** · enrollment: 52 (estimated)

## Conditions studied

- High-grade Glioma
- WHO Grade Ⅳ Glioma

## Interventions

- **BIOLOGICAL:** Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

## Key facts

- **NCT ID:** NCT06482905
- **Lead sponsor:** Tcelltech Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2026-09
- **Final completion:** 2027-06
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06482905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06482905, "Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06482905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*